American Herbal Products Association (AHPA) > News

AHPA Alerts

AHPA keeps members and the industry informed of recent news and developments that impact the trade through email alerts. Subscribe to news as it happens or a weekly summary of all alerts.

View recent alerts:

Legal Alerts >> News on dietary supplement laws, regulations and enforcement

Science Alerts >> The latest research on herbs and botanicals

Market Alerts>> Herbal market trends and AHPA-member press releases

Media Alerts >> Media coverage of the herbal industry

Medicinal Cannabis Alerts >> The latest research and news about medical cannabis

Cosmetic Alerts >> Regulatory updates and personal care product news

Subscribe to AHPA Updates to stay informed about the latest AHPA news and resources.

AHPA represents member interests at Cosmetic Ingredient Review meeting

AHPA attends Cosmetic Ingredient Review meeting finalizing Ginkgo biloba and eucalyptus cosmetic ingredient safety reports

American Herbal Products Association (AHPA) Chief Information Analyst Merle Zimmermann, Ph.D., attended the 147th Cosmetic Ingredient Review (CIR) Expert Panel Meeting on the safety of ingredients used in cosmetics held in Washington, D.C., Jun. 4-5. The meeting included discussions of two CIR safety reports being developed on Gingko biloba and eucalyptus cosmetic ingredients.

AHPA Presents at Canna West 2018

AHPA Chief Science Officer Dr. Johnson highlights AHPA resources for the cannabis industry

AHPA Chief Science Officer Holly Johnson, Ph.D., participated in a panel discussion yesterday on testing and labeling standards for cannabis products to increase product safety and decrease producers’ liability at Canna West 2018 held in Los Angeles.

AHPA recommends oshá harvest permitting in GMUG National Forests

Research supported by the AHPA ERB Foundation concludes plants have a high capacity for post‐harvest recolonization

AHPA recently submitted comments to the Grand Mesa, Uncompahgre and Gunnison (GMUG) National Forests to recommend that a revision of its plan for land and resource management include a process for permitting commercial harvest of oshá (Ligusticum porteri) root.

A Primer on AHPA’s Good Agricultural and Collection Practices and Good Manufacturing Practices (GACP-GMP) Guidance for Botanical Materials

What is AHPA's GACP-GMP guidance and how can it help your business?

Recorded May 22, 2018 -- Member cost: $150. Nonmember cost: $350.

Two-day Workshop: Microscopic Identification of Popular Botanical Materials

Familiarize yourself with various plant parts at the microscopic level to help you understand the characteristic cellular features of each plant part

June 27-28, 2018 -- Weber State University -- Ogden, UT

AHPA endorses the Hemp Farming Act of 2018

AHPA Board adopts policy to support any state or federal efforts to decriminalize hemp

AHPA is endorsing federal legislation recently introduced to decriminalize hemp and the AHPA Board of Trustees has adopted a policy for the association to support any future state or federal legislation to decriminalize the plant and all its derivatives.

The Art of Drying and Milling Botanicals

SOLD OUT!

July 16-17 -- Bighorn Botanicals -- Noxon, MT -- Member cost: $800. Nonmember cost: $1,000

IADSA update on international supplement regulations

IADSA April 2018 Newsflash

This issue of the IADSA Newsflash includes an update on EFSA's proposed limit of 800 mg/day for the intake of green tea catechins in food supplements

AHPA President Michael McGuffin urges companies selling kratom to comply with all applicable laws and regulations

Statement delivered during press conference

AHPA President Michael McGuffin stressed that any company looking to sell kratom or kratom products must comply with all applicable laws and regulations during a press conference.

AHPA recommends CBD not be scheduled under any international drug control convention

AHPA submits comments to FDA to inform participation in WHO Expert Committee on Drug Dependence

AHPA submitted comments to the Food and Drug Administration (FDA) yesterday to stress that cannabidiol (CBD) requires no international drug scheduling as an individual substance and encourage the U.S. to support this position.

Alerts

Subscribe>>